top of page
Next Generation Mucolytic
Replaces ions proven to be depleted under chronic inflammatory diseases
-
Sterile buffered ascorbic acid / glutathione solution delivered to the lung in a fixed dose combination
-
Strong safety profile – clean toxicology profile confirmed in clinical trials
-
Strong IP portfolio – composition, method of use, and NCE assets in 5 patent families
-
501(b)(1) pathway
ARINA-1 Restores Lung Health
1
Improves mucociliary clearance and ciliary expression / function
2
Decreases pathological inflammation
3
Direct antibacterial properties to protect the lungs
4
Improves quality of life and sputum markers of disease
Control
Normal Cilial Experssion
Viral Infection
Cilical Loss
Virus + ARINA-1
Restored Cilical Expression
Broad Applicability
Targets mucus and inflammation regardless of etiology
Initial Target Patient Population of >170 Million
Global Patients
Patient Diagnosis Today | Total Patients (in Millions) | With Mucus (in Millions) |
|---|---|---|
Lung Transplant | 0.05 | 0.04 |
NCFBE | 1 | 1 |
Chronic Bronchitis (CB) | 90 | 90 |
COPD (Non-CB) | 300 | 30 |
Asthma | 262 | 52 |
TOTAL WITH MUCUS >170M patients
Phase 2: ARINA-1 in Non-CF Bronchiectasis
Mechanism confirmed: improving sputum rheology and inflammatory markers improves quality of life in individuals with NCFBE
Changes in Sputum Biomarkers Confirm MOA
Sputum Viscosity
Sputum Neutrophil Elastase
ARINA-1 Improves Quality of Life
Met minimal clinically important difference at 28 days of use
Sustained impact 28 days after stopping therapy
St. George's Respiratory Questionnaire (SGRQ) | MCID: -4
SGRQ
ARINA-1 has Broad Applicability
-
Main entry criteria – non-bronchiectasis with mucus, no current exacerbation
-
62% of participants had improved quality of life
Join our newsletter to stay updated on news from the Renovion Team
bottom of page